MOUNTAIN VIEW, Calif.
July 30, 2013
/PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that the company's commercial partner
Grupo Ferrer Internacional
, S.A. has initiated sales of ADASUVE
inhalation powder, pre-dispensed (Staccato
Loxapine) in the European Union ("EU"). ADASUVE is now available in Germany. The first sale and shipment of product by Ferrer triggers a
milestone payment to Alexza, pursuant to the Company's collaboration agreement with Ferrer.
"This launch represents the first commercial sale of ADASUVE in the world, and marks the culmination of many years of dedicated effort and rigorous clinical development. I am incredibly proud of the efforts by the Alexza team and our partner Ferrer in bringing ADASUVE to physicians in the EU for use in their treatment of agitated patients with schizophrenia or bipolar disorder," said
Thomas B. King
, President and CEO of Alexza. "The initial launch of ADASUVE in
, followed by Ferrer's planned commercial roll out across the EU, is a key milestone for Alexza."
Alexza received marketing authorization for ADASUVE from the European Commission in February 2013. ADASUVE is the first inhalation therapy for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder authorized to be placed on the market in the EU. The marketing authorization for ADASUVE requires that patients receive regular treatment immediately after administration of the product to control acute agitation symptoms. It also requires that ADASUVE be administered only in a hospital setting under the supervision of a healthcare professional. Short-acting beta-agonist bronchodilator treatment should also be available for treatment of possible severe respiratory side-effects, such as bronchospasm.
"Alexza and Ferrer's effective cooperation has enabled a product launch of ADASUVE in an admirably short time following the EU approval in
, Chief Operating Officer of Ferrer. "ADASUVE is an important strategic product for Ferrer and we are excited to be introducing ADASUVE to the EU psychiatric and hospital treatment community."
Under the terms of the collaboration agreement between Alexza and Ferrer, which was announced in
, Alexza is the exclusive supplier of ADASUVE, responsible for all aspects of manufacture of the product. Alexza began manufacturing launch quantities of the product for the EU in the second quarter of 2013 at its
Mountain View, California
facility. The commercial product was shipped to Ferrer in
, and Ferrer completed EU product quality control release and final packaging in preparation for the planned third quarter launch. Ferrer is expected to launch ADASUVE in additional EU countries before year-end and will continue the EU launch into 2014.
Alexza and Ferrer estimate that as many as 8 million adults in the EU alone suffer from schizophrenia or bipolar disorder
. Agitation is a common symptom for these patients
, characterized by feelings of distress, anxiety and loss of control.
About ADASUVE ( Staccato loxapine)
ADASUVE combines Alexza's proprietary
system with loxapine, an antipsychotic medicinal product. The
system is a hand-held inhaler that delivers a drug aerosol to the deep lung that results in intravenous-like pharmacokinetics and rapid systemic effects.
ADASUVE has been approved for marketing in
the United States
by the U.S. Food and Drug Administration and in the EU by the European Commission. The authorization for ADASUVE in the EU differs from that in the U.S., with respect to the indication statement, dose regimen, available dose strengths, and risk mitigation and management plans.
For more information about ADASUVE, including the Summary of Product Characteristics and Patient Information Leaflet approved in the EU please visit:
. For the full prescribing information including boxed warnings for the U.S., please visit
Founded in 1959, Ferrer is a privately-held European R&D-based pharmaceutical company headquartered in Barcelona. It is active in the pharmaceutical, health, fine chemicals and food sectors in
and the United States. In total, Ferrer's human healthcare products are commercialized in more than 90 countries, through 27 international affiliates (including joint ventures) and 70 partners and distributors.
Ferrer carries out activities throughout the full pharmaceutical value chain, from R&D to international marketing, including fine chemical development and the manufacturing of both raw materials and finished pharmaceuticals. Its research centers in
, and manufacturing sites in
cover the pharmaceutical, diagnostics, vaccine, fine chemical, food and feed sectors.
Ferrer is Alexza's commercial partner for ADASUVE in
and the Commonwealth of Independent States countries.
For more information, visit